Valentina Boni, MD, PhD, University Hospital Quironsalud Madrid, Madrid, Spain, talks on novel antibody-drug conjugates (ADCs) in development, highlighting an ADC using a bispecific antibody targeting EGFR and HER-3 designed to deliver TOP1 inhibitor. This particular agent has shown a high overall-response rate (ORR) in EGFR-mutated non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma, which represents a new indication. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
